{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:51:26Z","timestamp":1791996686506,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012314","name":"Shinshu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K09863"],"award-info":[{"award-number":["JP21K09863"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K12891"],"award-info":[{"award-number":["JP24K12891"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bone.2026.118019","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:47:01Z","timestamp":1784562421000},"page":"118019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sacituzumab govitecan inhibits bone metastases of TROP2-expressing cancers"],"prefix":"10.1016","volume":"212","author":[{"given":"Toru","family":"Hiraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Horibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2026.118019_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bone.2026.118019_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1292211","article-title":"Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements","volume":"13","author":"Yao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bone.2026.118019_bb0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/dvdy.24242","article-title":"Trop2: from development to disease","volume":"244","author":"McDougall","year":"2015","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.bone.2026.118019_bb0020","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1038\/s41388-022-02220-1","article-title":"Trop-2, Na+\/K+ ATPase, CD9, PKC\u03b1, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion","volume":"41","author":"Guerra","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bone.2026.118019_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104971","article-title":"Trophoblast cell surface antigen-2 phosphorylation triggered by binding of galectin-3 drives metastasis through down-regulation of E-cadherin","volume":"299","author":"Iwamoto","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2026.118019_bb0030","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1158\/0008-5472.CAN-24-4855","article-title":"Extracellular domain shedding of TROP2 activates EGFR signaling to drive prostate cancer metastasis","volume":"85","author":"Liu","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2026.118019_bb0035","doi-asserted-by":"crossref","first-page":"e1480","DOI":"10.1093\/oncolo\/oyae168","article-title":"Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors","volume":"29","author":"Morgenstern-Kaplan","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2026.118019_bb0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody\u2013drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bone.2026.118019_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218622","article-title":"From linker stability to linker fitness: redefining ADC design for clinical translation","author":"Ma","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bone.2026.118019_bb0050","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2026.118019_bb0055","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2026.118019_bb0060","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR+HER2\u2212 metastatic breast cancer: the randomized phase 3 EVER-132-002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2026.118019_bb0065","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2026.118019_bb0070","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1078-0432.CCR-24-2523","article-title":"Sacituzumab govitecan in patients with relapsed\/refractory advanced head and neck squamous cell carcinoma: results from the phase II TROPiCS-03 basket study","volume":"31","author":"Michel","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2026.118019_bb0075","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2026.118019_bb0080","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1038\/s41467-018-05366-3","article-title":"A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries","volume":"9","author":"Kuchimaru","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bone.2026.118019_bb0085","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bone.2026.118019_bb0090","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-12-3801","article-title":"Cancer stem\u2013like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production","volume":"73","author":"Hiraga","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2026.118019_bb0095","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/labinvest.2014.1","article-title":"Colony-stimulating factor 1 potentiates lung cancer bone metastasis","volume":"94","author":"Hung","year":"2014","journal-title":"Lab. Investig."},{"key":"10.1016\/j.bone.2026.118019_bb0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.11586","article-title":"Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice","volume":"108","author":"Miki","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bone.2026.118019_bb0105","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bone.2026.118019_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7320","article-title":"Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer","volume":"13","author":"Weiten","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.bone.2026.118019_bb0115","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41598-020-58009-3","article-title":"Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan","volume":"10","author":"Zeybek","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2026.118019_bb0120","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2026.118019_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217350","article-title":"Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy","volume":"610","author":"Yu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bone.2026.118019_bb0130","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1535-7163.MCT-16-0219","article-title":"Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers","volume":"15","author":"Chang","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bone.2026.118019_bb0135","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.18632\/oncotarget.27766","article-title":"Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer","volume":"11","author":"Cardillo","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.bone.2026.118019_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194789","article-title":"Trophoblast cell surface antigen 2 (TROP2) as a predictive bio-marker for the therapeutic efficacy of sacituzumab govitecan in adenocarcinoma of the esophagus","volume":"14","author":"Hoppe","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bone.2026.118019_bb0145","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s00259-025-07106-4","article-title":"Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody\u2013drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer","volume":"52","author":"Huang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bone.2026.118019_bb0150","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2026.118019_bb0155","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1186\/s12885-022-10076-7","article-title":"Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer","volume":"22","author":"Jeon","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bone.2026.118019_bb0160","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40291-025-00814-5","article-title":"Inter-assay variability of TROP2 immunohistochemistry in triple-negative breast cancer","volume":"29","author":"Cursano","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.bone.2026.118019_bb0165","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.22.01063","article-title":"Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update","volume":"40","author":"Henry","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2026.118019_bb0170","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00280-025-04834-0","article-title":"Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences","volume":"95","author":"Zhou","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bone.2026.118019_bb0175","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/1535-7163.MCT-24-1176","article-title":"Preclinical pharmacokinetic, pharmacodynamic, and safety profile of OBI-992: a novel TROP2-targeted antibody\u2013drug conjugate","volume":"24","author":"Shia","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bone.2026.118019_bb0180","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.ccell.2025.09.012","article-title":"TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: a first-in-human phase 1 study","volume":"43","author":"Zhong","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226002450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226002450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:40:50Z","timestamp":1791996050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226002450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":36,"alternative-id":["S8756328226002450"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.118019","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacituzumab govitecan inhibits bone metastases of TROP2-expressing cancers","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.118019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118019"}}